title: Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration.
abstract: BACKGROUND
  Oncologic outcomes in men with radiation-recurrent prostate cancer (PCa) treated with salvage radical prostatectomy (SRP) are poorly defined.
  
  
  OBJECTIVE
  To identify predictors of biochemical recurrence (BCR), metastasis, and death following SRP to help select patients who may benefit from SRP.
  
  
  METHODS
  This is a retrospective, international, multi-institutional cohort analysis. There was a median follow-up of 4.4 yr following SRP performed on 404 men with radiation-recurrent PCa from 1985 to 2009 in tertiary centers.
  
  
  METHODS
  Open SRP.
  
  
  METHODS
  BCR after SRP was defined as a serum prostate-specific antigen (PSA) ≥ 0.1 or ≥ 0.2 ng/ml (depending on the institution). Secondary end points included progression to metastasis and cancer-specific death.
  
  
  CONCLUSIONS
  Median age at SRP was 65 yr of age, and median pre-SRP PSA was 4.5 ng/ml. Following SRP, 195 patients experienced BCR, 64 developed metastases, and 40 died from PCa. At 10 yr after SRP, BCR-free survival, metastasis-free survival, and cancer-specific survival (CSS) probabilities were 37% (95% confidence interval [CI], 31-43), 77% (95% CI, 71-82), and 83% (95% CI, 76-88), respectively. On preoperative multivariable analysis, pre-SRP PSA and Gleason score at postradiation prostate biopsy predicted BCR (p = 0.022; global p < 0.001) and metastasis (p = 0.022; global p < 0.001). On postoperative multivariable analysis, pre-SRP PSA and pathologic Gleason score at SRP predicted BCR (p = 0.014; global p < 0.001) and metastasis (p < 0.001; global p < 0.001). Lymph node involvement (LNI) also predicted metastasis (p = 0.017). The main limitations of this study are its retrospective design and the follow-up period.
  
  
  CONCLUSIONS
  In a select group of patients who underwent SRP for radiation-recurrent PCa, freedom from clinical metastasis was observed in >75% of patients 10 yr after surgery. Patients with lower pre-SRP PSA levels and lower postradiation prostate biopsy Gleason score have the highest probability of cure from SRP.
authors.affiliation: Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. dchade@gmail.com
authors.forename: Daher C
authors.initials: DC
authors.lastname: Chade
authors.forename: Shahrokh F
authors.initials: SF
authors.lastname: Shariat
authors.forename: Angel M
authors.initials: AM
authors.lastname: Cronin
authors.forename: Caroline J
authors.initials: CJ
authors.lastname: Savage
authors.forename: R Jeffrey
authors.initials: RJ
authors.lastname: Karnes
authors.forename: Michael L
authors.initials: ML
authors.lastname: Blute
authors.forename: Alberto
authors.initials: A
authors.lastname: Briganti
authors.forename: Francesco
authors.initials: F
authors.lastname: Montorsi
authors.forename: Henk G
authors.initials: HG
authors.lastname: van der Poel
authors.forename: Hendrik
authors.initials: H
authors.lastname: Van Poppel
authors.forename: Steven
authors.initials: S
authors.lastname: Joniau
authors.forename: Guilherme
authors.initials: G
authors.lastname: Godoy
authors.forename: Antonio
authors.initials: A
authors.lastname: Hurtado-Coll
authors.forename: Martin E
authors.initials: ME
authors.lastname: Gleave
authors.forename: Marcos
authors.initials: M
authors.lastname: Dall'Oglio
authors.forename: Miguel
authors.initials: M
authors.lastname: Srougi
authors.forename: Peter T
authors.initials: PT
authors.lastname: Scardino
authors.forename: James A
authors.initials: JA
authors.lastname: Eastham
mesh_terms: D000368:Aged; D001706:Biopsy; D018572:Disease-Free Survival; D005060:Europe; D006801:Humans; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D018579:Patient Selection; D016016:Proportional Hazards Models; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy / Q000009:adverse effects / Q000401:mortality; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D016879:Salvage Therapy; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States
chemical_list: D017430:Prostate-Specific Antigen